Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum β-lactamases producing <em>Enterobacterales</em> (ESBL-E), carbapenem-resistant <em>Enterobacterales</em> (CRE), and <em>Pseudomonas aeruginosa</em> with difficult-to-treat resistance (DTR-<em>P. aeruginosa</em>)

Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum β-lactamases producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa)

PDF(1001 KB)

PDF(1001 KB)

Chinese Journal of Infection and Chemotherapy ›› 2023, Vol. 23 ›› Issue (2) : 265-271. DOI: 10.16718/j.1009-7708.2023.02.022

Review and Compilation

Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum β-lactamases producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa)

{{article.zuoZhe_EN}}

Author information +

History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

Cite this article

Download Citations

{{article.zuoZheEn_L}}. {{article.title_en}}. {{journal.qiKanMingCheng_EN}}. 2023, 23(2): 265-271 https://doi.org/10.16718/j.1009-7708.2023.02.022

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}

{{article.copyrightLicense_en}}

PDF(1001 KB)

Accesses

Citation

Detail

Sections

Recommended

/

〈

〉